Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome
Biomarkers in Cancer · 2019
DOI: 10.1177/1179299x19854447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomarkers in Cancer, 2019. Verfasst von Havva Keskin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Istanbul Medeniyet University Training and Research Hospital, Istanbul, Turkey. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the development of these symptoms and signs, their pathophysiology has not been discovered completely yet. They are usually mild, but they may rarely progress to the severe stage of “Systemic Capillary Leak Syndrome” with a high mortality rate. The objective of this study was to investigate the association between the serum levels of interleukin-2 (IL-2), interleukin-11 (IL-11), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), and these symptoms and signs. A total of 44 cancer patients who had neither heart, lung, liver, renal, or thyroid disease were recruited into this study. Their symptoms and signs were examined and questioned before the first cycle of the first chemotherapy treatment and the 24 h after this chemotherapy. All participant’s serum samples were taken, and the VEGF, TNF, IL-2, and IL-11 levels were studied. There was no association between the chemotherapeutic drugs, and the symptoms and signs such as edema, dyspnea, coughing, and flu-like symptoms. There was a significant decrease in IL-11 levels in the other treatment group compared with the group receiving paclitaxel, docetaxel, gemcitabine, and vinorelbine in the first day following chemotherapy ( P = .006). However, no relation was observed between the symptoms and signs, the response to the chemotherapy, and the serum levels of VEGF, TNF, IL-2, and IL-11. These symptoms and life-threatening syndrome have been a current topic between the clinicians. Although some drugs and mediators are accused, its pathophysiology has not been discovered completely yet. In this study, we could not detect any association between the symptoms, signs, and the cytokine levels following the chemotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Istanbul Medeniyet University Training and Research Hospital, Istanbul, Turkey.
- Department of Internal Medicine, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.
- Department of Medical Oncology, Faculty of Medicine, University of Ankara, Ankara, Turkey.
- Department of Medical Oncology, Faculty of Medicine, University of Yildirim Beyazit and Atatürk Training and Research Hospital, Ankara, Turkey.
ORCID-Profile: Havva Keskin
Zitieren
APA
Keskin, H., Cadirci, K., Demirkazik, A., Akbulut, H., & Yalcin, B. (2019). Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome. Biomarkers in Cancer. https://doi.org/10.1177/1179299x19854447
Vancouver
Keskin H, Cadirci K, Demirkazik A, Akbulut H, Yalcin B. Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome. Biomarkers in Cancer. 2019. doi:10.1177/1179299x19854447
BibTeX
@article{Keskin2019,
author = {Keskin, Havva and Cadirci, Kenan and Demirkazik, Ahmet and Akbulut, Hakan and Yalcin, Bulent},
title = {Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome},
journal = {Biomarkers in Cancer},
year = {2019},
doi = {10.1177/1179299x19854447}
}
EUVIMED